You are viewing: China Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The China Plasma Fractionation Market was valued at $3395.2 Million in 2026 and projected to reach to $5216.6 Million by 2031, representing a compound annual growth rate of 9.0%. China's plasma fractionation market is positioned for substantial growth over the forecast period, supported by demographic shifts, healthcare modernization, and expanding clinical applications.

China Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Plasma Fractionation Market Trends and Insights

  • This expansion reflects China's increasing demand for immunoglobulin therapies, albumin products, and clotting factor concentrates driven by an aging population and rising prevalence of chronic diseases.
  • China's strengthening regulatory framework and investment in domestic plasma collection infrastructure are positioning the country as a key player in the Asia Pacific plasma fractionation landscape. The Chinese market benefits from government initiatives promoting self-sufficiency in plasma-derived therapeutics and growing healthcare expenditure across urban and rural regions.
  • China's plasma fractionation sector is characterized by both multinational presence and emerging domestic manufacturers scaling production capabilities.
  • Between 2026 and 2031, China is expected to capture significant market share through enhanced manufacturing capacity, improved cold chain logistics, and expanded patient access to plasma-derived medicines, solidifying its role as a critical growth engine within the broader Asia Pacific region..

Key Market Statistics

  • CAGR (2026-2031) 9.0% CAGR
  • Market Size, 2026 ~USD 3395.2 Million
  • Forecast, 2031 ~USD 5216.6 Million
  • Country China

China Plasma Fractionation Market Overview

Rapid Market Expansion :

China's plasma fractionation market is projected to grow from USD 3,395.2 million in 2026 to USD 5,216.6 million by 2031, driven by a 9.0% CAGR, significantly outpacing the global growth rate of 7.6%.

Aging Population Dynamics :

China's rapidly aging demographic is driving increased demand for immunoglobulin therapies, albumin products, and clotting factor concentrates, creating sustained market opportunities for plasma-derived therapeutics.

Government Healthcare Initiatives :

Enhanced healthcare infrastructure investments and national policies promoting self-sufficiency in plasma collection and fractionation are strengthening domestic production capabilities and market accessibility across China.

Rising Disease Prevalence :

Increasing incidence of immunodeficiency disorders, bleeding disorders, and chronic diseases in China is escalating the clinical demand for plasma fractionation products and specialized therapeutic interventions.

China Plasma Fractionation Market Dynamics

  • The country's commitment to developing domestic plasma collection infrastructure and reducing import dependency will drive market consolidation and innovation.
  • Rising healthcare expenditure and improved patient access to advanced therapies will further accelerate market penetration across urban and emerging regional markets. The competitive landscape in China is intensifying as both domestic manufacturers and international players invest in production facilities and distribution networks.
  • Regulatory improvements and standardization of plasma collection practices will enhance product quality and market confidence.
  • Strategic partnerships, mergers, and acquisitions are expected to reshape the market structure, with emphasis on developing cost-effective solutions tailored to China's healthcare system requirements and patient demographics..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • China's plasma fractionation market will grow from USD 3,395.2M (2026) to USD 5,216.6M (2031) at a 9.0% CAGR, outpacing global growth.
      • China's aging population and rising chronic disease prevalence are primary drivers of demand for immunoglobulin and albumin therapies.
      • Government self-sufficiency initiatives and regulatory improvements are accelerating domestic plasma collection and manufacturing capacity in China.
      • China's expanding healthcare infrastructure and cold chain logistics will enable broader patient access to plasma-derived medicines by 2031.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      China Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical Manufacturers : Plasma fractionation companies need China-specific market data to evaluate market entry opportunities, assess competitive positioning, and develop localized product strategies aligned with Chinese healthcare regulations and patient needs.
      • Healthcare Investors & PE Firms : Investment professionals require detailed China market analysis to identify high-growth opportunities, evaluate acquisition targets, and make informed capital allocation decisions in the expanding plasma therapeutics sector.
      • Hospital & Clinical Networks : Healthcare providers and hospital administrators need market insights to forecast plasma product demand, optimize procurement strategies, and plan therapeutic program development for their patient populations.
      • Government & Policy Makers : Chinese healthcare authorities and policy officials require market intelligence to inform healthcare infrastructure planning, plasma collection policies, and regulatory frameworks supporting domestic industry development.
      • Distributors & Supply Chain Partners : Logistics providers and pharmaceutical distributors need China market data to identify growth regions, optimize distribution networks, and develop partnerships with manufacturers and healthcare facilities across the country.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise market valuation for China (USD 3,395.2M in 2026) and verified 5-year forecast data to support investment decisions, business planning, and competitive positioning strategies in this high-growth market.
      • China-Specific Demand Drivers : Understand localized factors including aging population trends, disease prevalence patterns, and healthcare policy changes unique to China that differentiate it from global market dynamics and create targeted growth opportunities.
      • Competitive Intelligence : Analyze China's domestic and international player landscape, market consolidation trends, and regulatory environment to identify partnership opportunities, market entry strategies, and competitive advantages specific to the Chinese market.
      • Regional Market Segmentation : Access detailed insights into China's regional variations, urban versus rural market dynamics, and tier-1 to tier-3 city penetration rates to optimize distribution strategies and resource allocation across the country.
      • Strategic Planning & Forecasting : Leverage China-focused market projections and trend analysis to develop accurate financial models, set realistic revenue targets, and align product development roadmaps with anticipated market evolution through 2031.

      Frequently asked questions

      What is the projected size of China's plasma fractionation market in 2031?

      China's plasma fractionation market is projected to reach USD 5,216.6 million by 2031, growing from USD 3,395.2 million in 2026.

      What is the CAGR for China's plasma fractionation market?

      China's plasma fractionation market is expected to grow at a compound annual growth rate of 9.0% between 2026 and 2031.

      What are the main drivers of growth in China's plasma fractionation market?

      Key drivers include China's aging population, rising prevalence of chronic diseases, government self-sufficiency initiatives, improved regulatory frameworks, and expanding healthcare infrastructure.

      Which plasma-derived products are most in demand in China?

      China shows strong demand for immunoglobulin therapies, albumin products, and clotting factor concentrates, driven by clinical needs and patient demographics.

      How is China's regulatory environment supporting plasma fractionation market growth?

      China's strengthening regulatory framework and government policies promoting domestic plasma collection and manufacturing are enhancing market conditions and attracting investment in the sector.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status